Related references
Note: Only part of the references are listed.PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas
Aaron Goodman et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma
Jeffrey S. Weber et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade
Pornpimol Charoentong et al.
CELL REPORTS (2017)
Targetable genetic features of primary testicular and primary central nervous system lymphomas
Bjoern Chapuy et al.
BLOOD (2016)
Cancer Neoantigens and Applications for Immunotherapy
Alexis Desrichard et al.
CLINICAL CANCER RESEARCH (2016)
Genetic basis of PD-L1 overexpression in diffuse large B-cell lymphomas
Konstantinos Georgiou et al.
BLOOD (2016)
Frequent CTLA4-CD28 gene fusion in diverse types of T-cell lymphoma
Hae Yong Yoo et al.
HAEMATOLOGICA (2016)
Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure
Philippe Armand et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study
Alexander M. Lesokhin et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy
Weijie Ma et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)
PD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma
Xi-wen Bi et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)
Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial
Anas Younes et al.
LANCET ONCOLOGY (2016)
Multiple myeloma causes clonal T-cell immunosenescence: identification of potential novel targets for promoting tumour immunity and implications for checkpoint blockade
H. Suen et al.
LEUKEMIA (2016)
Aberrant PD-L1 expression through 3′-UTR disruption in multiple cancers
Keisuke Kataoka et al.
NATURE (2016)
Computational genomics tools for dissecting tumour-immune cell interactions
Hubert Hackl et al.
NATURE REVIEWS GENETICS (2016)
Ipilimumab for Patients with Relapse after Allogeneic Transplantation
Matthew S. Davids et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade
Pei-Ling Chen et al.
CANCER DISCOVERY (2016)
Frequent CTLA4-CD28 gene fusion in diverse types of T-cell lymphoma
Hae Yong Yoo et al.
HAEMATOLOGICA (2016)
Myeloma Drug Resistance Induced by Binding of Myeloma B7-H1 (PD-L1) to PD-1
Mariko Ishibashi et al.
CANCER IMMUNOLOGY RESEARCH (2016)
Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma
Junichi Kiyasu et al.
BLOOD (2015)
Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma
Guellue Goerguen et al.
CLINICAL CANCER RESEARCH (2015)
Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center
Troy Z. Horvat et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
T cells are functionally not impaired in AML: increased PD-1 expression is only seen at time of relapse and correlates with a shift towards the memory T cell compartment
Frauke M. Schnorfeil et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2015)
Increase of PD-L1 expressing B-precursor ALL cells in a patient resistant to the CD19/CD3-bispecific T cell engager antibody blinatumomab
Thomas Koehnke et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2015)
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
Antoni Ribas et al.
LANCET ONCOLOGY (2015)
PD-L1/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma
B. Paiva et al.
LEUKEMIA (2015)
Targeting PD1-PDL1 immune checkpoint in plasmacytoid dendritic cell interactions with T cells, natural killer cells and multiple myeloma cells
A. Ray et al.
LEUKEMIA (2015)
Genomic analysis of mycosis fungoides and Sezary syndrome identifies recurrent alterations in TNFR2
Alexander Ungewickell et al.
NATURE GENETICS (2015)
Integrated molecular analysis of adult T cell leukemia/lymphoma
Keisuke Kataoka et al.
NATURE GENETICS (2015)
Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer
Edward B. Garon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Stephen M. Ansell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
Naiyer A. Rizvi et al.
SCIENCE (2015)
Immunomodulatory molecule PD-L1 is expressed on malignant plasma cells and myeloma-propagating pre-plasma cells in the bone marrow of multiple myeloma patients
S. Yousef et al.
BLOOD CANCER JOURNAL (2015)
PDL1 Expression on Plasma and Dendritic Cells in Myeloma Bone Marrow Suggests Benefit of Targeted anti PD1-PDL1 Therapy
Anne-Marit Sponaas et al.
PLOS ONE (2015)
Personalized treatment of Sezary syndrome by targeting a novel CTLA4: CD28 fusion
Aleksandar Sekulic et al.
MOLECULAR GENETICS & GENOMIC MEDICINE (2015)
Expression of Programmed Cell Death 1 Ligand 2 (PD-L2) Is a Distinguishing Feature of Primary Mediastinal (Thymic) Large B-cell Lymphoma and Associated With PDCD1LG2 Copy Gain
Min Shi et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2014)
Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma
David D. W. Twa et al.
BLOOD (2014)
FOXP3 and CTLA4 overexpression in multiple myeloma bone marrow as a sign of accumulation of CD4+ T regulatory cells
Walter Moises Tobias Braga et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2014)
LSECtin Expressed on Melanoma Cells Promotes Tumor Progression by Inhibiting Antitumor T-cell Responses
Feng Xu et al.
CANCER RESEARCH (2014)
Prevalence and Clinical Implications of Epstein-Barr Virus Infection in De Novo Diffuse Large B-Cell Lymphoma in Western Countries
Chi Young Ok et al.
CLINICAL CANCER RESEARCH (2014)
Clinical Implications of Phosphorylated STAT3 Expression in De Novo Diffuse Large B-cell Lymphoma
Chi Young Ok et al.
CLINICAL CANCER RESEARCH (2014)
Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents
H. Yang et al.
LEUKEMIA (2014)
High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial
D. Rossille et al.
LEUKEMIA (2014)
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
Matthew M. Gubin et al.
NATURE (2014)
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
Thomas Powles et al.
NATURE (2014)
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Roy S. Herbst et al.
NATURE (2014)
PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies
Benjamin J. Chen et al.
CLINICAL CANCER RESEARCH (2013)
Oncology Meets Immunology: The Cancer-Immunity Cycle
Daniel S. Chen et al.
IMMUNITY (2013)
Impaired Proteasome Function Activates GATA3 in T Cells and Upregulates CTLA-4: Relevance for Sezary Syndrome
Heather M. Gibson et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2013)
Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma
H. Tamura et al.
LEUKEMIA (2013)
Tumor Infiltrating PD1-Positive Lymphocytes and the Expression of PD-L1 Predict Poor Prognosis of Soft Tissue Sarcomas
Jung Ryul Kim et al.
PLOS ONE (2013)
Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells
Stefani Spranger et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
Standardization of whole blood immune phenotype monitoring for clinical trials: panels and methods from the ONE study
Mathias Streitz et al.
TRANSPLANTATION RESEARCH (2013)
Molecular mechanisms of T cell co-stimulation and co-inhibition
Lieping Chen et al.
NATURE REVIEWS IMMUNOLOGY (2013)
Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape
Seng-Ryong Woo et al.
CANCER RESEARCH (2012)
PD-1 inhibits T cell proliferation by upregulating p27 and p15 and suppressing Cdc25A
Nikolaos Patsoukis et al.
CELL CYCLE (2012)
Constitutive AP-1 Activity and EBV Infection Induce PD-L1 in Hodgkin Lymphomas and Posttransplant Lymphoproliferative Disorders: Implications for Targeted Therapy
Michael R. Green et al.
CLINICAL CANCER RESEARCH (2012)
IL-12 upregulates TIM-3 expression and induces T cell exhaustion in patients with follicular B cell non-Hodgkin lymphoma
Zhi-Zhang Yang et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1
Shigeki Chiba et al.
NATURE IMMUNOLOGY (2012)
Bat3 promotes T cell responses and autoimmunity by repressing Tim-3-mediated cell death and exhaustion
Manu Rangachari et al.
NATURE MEDICINE (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Tumour Cell Generation of Inducible Regulatory T-Cells in Multiple Myeloma Is Contact-Dependent and Antigen-Presenting Cell-Independent
Sylvia Feyler et al.
PLOS ONE (2012)
Immunosuppressive Effects of Multiple Myeloma Are Overcome by PD-L1 Blockade
William H. D. Hallett et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2011)
Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia
Qing Zhou et al.
BLOOD (2011)
Anti-TIM3 Antibody Promotes T Cell IFN-γ-Mediated Antitumor Immunity and Suppresses Established Tumors
Shin Foong Ngiow et al.
CANCER RESEARCH (2011)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Programmed Death Ligand 1 Is Expressed by Non-Hodgkin Lymphomas and Inhibits the Activity of Tumor-Associated T Cells
David J. Andorsky et al.
CLINICAL CANCER RESEARCH (2011)
PD-1 Blockade by CT-011, Anti-PD-1 Antibody, Enhances Ex Vivo T-cell Responses to Autologous Dendritic Cell/Myeloma Fusion Vaccine
Jacalyn Rosenblatt et al.
JOURNAL OF IMMUNOTHERAPY (2011)
PD-L2 is expressed on activated human T cells and regulates their function
Nassima Messal et al.
MOLECULAR IMMUNOLOGY (2011)
Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma
Michael R. Green et al.
BLOOD (2010)
Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia
Qing Zhou et al.
BLOOD (2010)
Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients
Julien Fourcade et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2010)
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
Kaori Sakuishi et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer
Junko Matsuzaki et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation
Asad Bashey et al.
BLOOD (2009)
PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model
Long Zhang et al.
BLOOD (2009)
Phase I Study of Ipilimumab, an Anti-CTLA-4 Monoclonal Antibody, in Patients with Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma
Stephen M. Ansell et al.
CLINICAL CANCER RESEARCH (2009)
Discovery of a functional immunoreceptor tyrosine-based switch motif in a 7-transmembrane-spanning receptor: role in the orexin receptor OX1R-driven apoptosis
Aadil El Firar et al.
FASEB JOURNAL (2009)
High Numbers of Tumor-Infiltrating Programmed Cell Death 1-Positive Regulatory Lymphocytes Are Associated With Improved Overall Survival in Follicular Lymphoma
Joaquim Carreras et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
Loise M. Francisco et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2009)
Functionally Distinct LAG-3 and PD-1 Subsets on Activated and Chronically Stimulated CD8 T Cells
Joseph F. Grosso et al.
JOURNAL OF IMMUNOLOGY (2009)
LAG-3 Regulates Plasmacytoid Dendritic Cell Homeostasis
Creg J. Workman et al.
JOURNAL OF IMMUNOLOGY (2009)
CTLA-4 genotype and relapse incidence in patients with acute myeloid leukemia in first complete remission after induction chemotherapy
A. Perez-Garcia et al.
LEUKEMIA (2009)
PD-1, a follicular T-cell marker useful for recognizing nodular lymphocyte-predominant Hodgkin lymphoma
Syong H. Nam-Cha et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2008)
PD-1 and its ligands in tolerance and immunity
Mary E. Keir et al.
ANNUAL REVIEW OF IMMUNOLOGY (2008)
PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma
Ryo Yamamoto et al.
BLOOD (2008)
Programmed death 1 is a marker of angioimmunoblastic T-Cell lymphoma and B-cell small lymphocytic lymphoma/chronic lymphocytic leukemia
Luc Xerri et al.
HUMAN PATHOLOGY (2008)
Immunoreceptor tyrosine-based inhibition motifs:: a quest in the past and future
Marc Daeron et al.
IMMUNOLOGICAL REVIEWS (2008)
Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)
Michal Marzec et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-γ and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway
Jizhong Liu et al.
BLOOD (2007)
PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma
R. Houston Thompson et al.
CLINICAL CANCER RESEARCH (2007)
PAG-associated FynT regulates calcium signaling and promotes anergy in T lymphocytes
Dominique Davidson et al.
MOLECULAR AND CELLULAR BIOLOGY (2007)
Increased expression of CTLA-4 in malignant T cells from patients with mycosis fungoides - Cutaneous T-cell lymphoma
Henry K. Wong et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2006)
The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity
C Zhu et al.
NATURE IMMUNOLOGY (2005)
PD-L2:PD-1 involvement in T cell proliferation, cytokine production, and integrin-mediated adhesion
PA Saunders et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2005)
CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms
RV Parry et al.
MOLECULAR AND CELLULAR BIOLOGY (2005)
Expression of lymphocyte activation gene 3 (LAG-3) on B cells is induced by T cells
M Kisielow et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2005)
Structural and functional analysis of the costimulatory receptor programmed death-1
XW Zhang et al.
IMMUNITY (2004)
PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells
C Blank et al.
CANCER RESEARCH (2004)
PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3ζ signalosome and downstream signaling to PKCθ
KA Sheppard et al.
FEBS LETTERS (2004)
B7-1 and B7-2 selectively recruit CTLA-4 and CD28 to the immunological synapse
T Pentcheva-Hoang et al.
IMMUNITY (2004)
Differential expression of CTLA-4 among T cell subsets
CB Jago et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2004)
In a model of tumor dormancy, long-term persistent leukemic cells have increased B7-H1 and B7.1 expression and resist CTL-mediated lysis
A Saudemont et al.
BLOOD (2004)
Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity
TJ Curiel et al.
NATURE MEDICINE (2003)
The CD4-related molecule, LAG-3 (CD223), regulates the expansion of activated T cells
CJ Workman et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2003)
Program death-1 engagement upon TCR activation has distinct effects on costimulation and cytokine-driven proliferation: Attenuation of ICOS, IL-4, and IL-21, but not CD28, IL-7, and IL-15 responses
F Bennett et al.
JOURNAL OF IMMUNOLOGY (2003)
Cutting edge: Molecular analysis of the negative regulatory function of lymphocyte activation gene-3
CJ Workman et al.
JOURNAL OF IMMUNOLOGY (2002)
Expression of programmed death 1 ligands by murine T cells and APC
T Yamazaki et al.
JOURNAL OF IMMUNOLOGY (2002)
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade
Y Iwai et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Surface cytotoxic T lymphocyte-associated antigen 4 partitions within lipid rafts and relocates to the immunological synapse under conditions of inhibition of T cell activation
PJ Darlington et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2002)
Inhibition of CTLA-4 function by the regulatory subunit of serine/threonine phosphatase 2A
ML Baroja et al.
JOURNAL OF IMMUNOLOGY (2002)
CTLA-4 suppresses proximal TCR signaling in resting human CD4+ T cells by inhibiting ZAP-70 Tyr319 phosphorylation:: A potential role for tyrosine phosphatases
C Guntermann et al.
JOURNAL OF IMMUNOLOGY (2002)
Negative effect of CTLA-4 on induction of T-cell immunity in vivo to B7-1+, but not B7-2+, marine myelogenous leukemia
JL LaBelle et al.
BLOOD (2002)
Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease
L Monney et al.
NATURE (2002)
Cytotoxic T lymphocyte antigen-4 accumulation in the immunological synapse is regulated by TCR signal strength
JG Egen et al.
IMMUNITY (2002)
B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells
SY Tseng et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2001)
Crystal structure of the B7-1/CTLA-4 complex that inhibits human immune responses
CC Stamper et al.
NATURE (2001)
PD-L2 is a second ligand for PD-I and inhibits T cell activation
Y Latchman et al.
NATURE IMMUNOLOGY (2001)
The expanding B7 superfamily: Increasing complexity in costimulatory signals regulating T cell function
AJ Coyle et al.
NATURE IMMUNOLOGY (2001)
Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice
H Nishimura et al.
SCIENCE (2001)
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation
GJ Freeman et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
CTLA-4 (CD152) can inhibit T cell activation by two different mechanisms depending on its level of cell surface expression
BM Carreno et al.
JOURNAL OF IMMUNOLOGY (2000)
Immunologic self-tolerance maintained by CD25+CD4+ regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4
T Takahashi et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)